David Engelhardt
David Engelhardt has been employed in equity research at TraderFox GmbH since April 2022. David completed his Bachelor's degree in Economics at Friedrich-Alexander-University in Erlangen-Nuremberg in 2018 and subsequently obtained a Master's degree in Business Administration at the University of Bamberg. Since 2019, he has been independently engaged with the topics of stock markets, equities, and capital markets. For the equity magazine, he is mainly responsible for the Hot News section and regularly publishes his own articles there. Since March 2023, he has been reporting as the editor-in-chief for the Traderfox equity magazine Small Caps Investor about small companies with enormous growth potential.
Latest from David Engelhardt
BrightSpring Health Services: The Silent Giant in the US Care Market
Chefs' Warehouse: Exclusivity on the Plate: How to Conquer Fine Dining
Chefs' Warehouse exclusively supplies the upscale gastronomy sector with specialties and secures noticeably...
RingCentral: Phone Calls Are a Thing of the Past: The Company is Opening the Next Growth Chapter with Voice AI
RingCentral has transformed from a loss-making growth SaaS provider to a highly profitable cloud communication...
Revolution Medicines: The Attack on the Unbreakable Cancer Code
Revolution Medicines develops novel compounds that specifically block the active form of cancer-causing...
NVE Corporation: The Highly Profitable Niche King of Spintronics
NVE is a highly specialized pioneer in the field of spintronics, providing essential components for...
10x Genomics: Technology Leader in Next-Generation Genomics
The high-margin "razor-and-blades business model" provides the technology leader with reliable, recurring...
First Advantage: The Data Octopus in the Recruiting Market
First Advantage occupies a critical niche in the HR sector as a leading data and software platform...
Liquidia Corporation: From Treprostinil Pioneer to Highly Profitable Pharma Player
Liquidia utilizes its patented PRINT® platform to transform established active ingredients like Treprostinil...
World Kinect: The Invisible Vein of Global Trade Before the Margin Leap
As a customer-oriented intermediary, World Kinect connects global energy producers with logistics...
Victoria’s Secret & Co.: Rise, Fall, and Resurrection
The radical image shift away from the "Angels" towards comfort and inclusion has breathed new life...
Trevi Therapeutics: The Code Against Chronic Cough
Trevi Therapeutics has approximately $334 million in liquid assets thanks to successful capital increases,...
Fastly: The Edge Revolution: Is the Company now Starting its Second Spring?
Fastly accelerates the internet and secures web applications by processing data through a decentralized...
Vishay Intertechnology: The Invisible Nervous System of the Global Economy
As one of the world's leading manufacturers of passive components and discrete semiconductors, Vishay...
Erasca: Here's how the Biotech Company Aims to Revolutionize Oncology
Erasca is a pure development company in precision oncology that currently has no products on the market...
Immix Biopharma: The Hunt for the Medical Bullseye
Immix Biopharma has a highly effective asset with its CAR-T cell therapy NXC-201, which has achieved...
Ciena Corp.: The Indispensable Giant in the Shadow of AI Titans
Ciena benefits massively as the physical "nervous system" from the AI boom, as the company provides...
Personalis Inc.: Precision Medicine at the Commercial Turning Point: Can This Biotech Bet Pay Off?
The business model is rapidly transforming from a pure research service provider to a clinical diagnostics...
Nektar Therapeutics: Full Focus on the Billion-Dollar Market of Immunology
Nektar Therapeutics generates its revenue not from selling its own medications, but from the research...
Ligand Pharmaceuticals: The Highly Profitable License Powerhouse of the Biotech Industry
Thanks to a business model solely based on licenses and royalty fees, Ligand Pharmaceuticals filters...
Spyre Therapeutics: a new Approach in the Billion-Dollar Market of Immunology
Spyre Therapeutics minimizes biological development risk by technologically optimizing already scientifically...
Butterfly Network: The Healthcare Revolution for Your Pocket
Butterfly Network replaces expensive, traditional ultrasound crystals with a single, low-cost silicon...